How to cite item

Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients

	author = {Damian von Eiff and Farastuk Bozorgmehr and Inn Chung and Denise Bernhardt and Stefan Rieken and Stephan Liersch and Thomas Muley and Sonja Kobinger and Michael Thomas and Petros Christopoulos and Martin Steins},
	title = {Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients},
	journal = {Journal of Thoracic Disease},
	volume = {12},
	number = {3},
	year = {2020},
	keywords = {},
	abstract = {Background: Etoposide-/platinum-based chemotherapy is the standard first-line treatment for extensive- disease small cell lung cancer (SCLC), but responses are short-lived and subsequent options limited. Here, we present our experience with paclitaxel in advanced treatment lines.
Methods: We retrospectively studied the clinical course of all paclitaxel-treated SCLC patients between 2005 and 2015 in our institution. Prognostic and predictive factors were analyzed by Kaplan-Meier and Cox regression analyses.
Results: A total of 185 patients [119 men, median age 65 years, median ECOG performance status (PS) 1] were identified. One hundred and sixty-eight patients had extensive disease (ED) at the time of paclitaxel therapy. Paclitaxel was mainly given as third- or fourth-line therapy (93%). The response rate (RR) was 17% and disease control rate (DCR) 28%. Patients reached a median progression-free survival (PFS) of 1.6 (95% CI: 1.4–1.8) months and median overall survival (OS) of 3.3 (95% CI: 2.8–3.9) months. Main toxicities were fatigue (25%) and polyneuropathy (17%). Dose reduction of ≥25% was associated with shorter PFS [1.9 (95% CI: 1.5–2.3) vs. 1.4 (95% CI: 1.3–1.5) months; P=0.004]. Further independent predictive factors for PFS were gender, age, and hepatic/brain metastases (P},
	issn = {2077-6624},	url = {}